Detalles de la búsqueda
1.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36797356
2.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29449192
3.
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.
J Pharmacokinet Pharmacodyn
; 43(2): 123-35, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26837775
4.
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Clin Transl Sci
; 17(3): e13769, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38515348
5.
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
Clin Pharmacol Ther
; 2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519861
6.
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
Clin Pharmacol Ther
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752712
7.
Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
Drug Metab Dispos
; 41(2): 508-17, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23223496
8.
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Drug Metab Dispos
; 41(12): 2104-13, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24041744
9.
Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.
Mol Pharm
; 10(11): 4032-7, 2013 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23980906
10.
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
Mol Pharm
; 10(11): 4055-62, 2013 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24044612
11.
Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction.
Biomed Chromatogr
; 27(1): 102-10, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22623056
12.
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.
Biopharm Drug Dispos
; 34(3): 141-54, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23225350
13.
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors.
CPT Pharmacometrics Syst Pharmacol
; 12(1): 95-109, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36330700
14.
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
J Immunother Cancer
; 11(10)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37857528
15.
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Biomedicines
; 9(9)2021 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34572463
16.
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
Cancer Chemother Pharmacol
; 88(6): 921-930, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34471960
17.
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.
CPT Pharmacometrics Syst Pharmacol
; 10(10): 1221-1235, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34346168
18.
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
Clin Pharmacol Ther
; 105(2): 486-495, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30058723
19.
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
CPT Pharmacometrics Syst Pharmacol
; 8(4): 240-248, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30762302
20.
Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
Curr Med Chem
; 15(8): 809-25, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18393850